News

Diabetes, which causes blood sugar levels to rise abnormally, may trigger a stronger immune response and worsen myasthenia gravis (MG) symptoms, a study in a rat disease model suggests. If its findings hold true in people, they could provide evidence of the importance of blood sugar control in easing…

A 31-year-old woman was diagnosed with two autoimmune conditions — myasthenia gravis (MG) and a liver disease called primary biliary cirrhosis — after giving birth, a recent case study reported. “Given the fluctuation of the immune status during the postpartum period, combined autoimmune diseases need to be taken into…

An extremely rare case of myasthenia gravis (MG) associated with paroxysmal nocturnal hemoglobinuria (PNH) and aplastic anemia (AA), two bone marrow failure conditions in which the immune system mistakenly attacks developing red blood cells, was reported recently. The report, “Myasthenia gravis and paroxysmal nocturnal hemoglobinuria after thymectomy: A…

Older age, moderate‐to‐severe anemia, and extremely high white blood cell counts were significant predictors of in‐hospital mortality in myasthenia gravis (MG) patients having a myasthenic crisis — marked by severe difficulties in breathing that require mechanical ventilation — a study from Taiwan reported. The study, “Hemogram parameters can…

The Institute for Clinical and Economic Review (ICER), an independent nonprofit that evaluates the prices and benefits of medications in the U.S., reported on the efficacy and cost-effectiveness of Soliris (eculizumab) and efgartigimod. Its report found reasonable evidence that adding either of these medications to conventional care could…

Global Genes has partnered with the Rare Disease Diversity Coalition (RDDC) to advance health equity for rare disease patients and caregivers in underrepresented communities of color. “For rare disease patients, there are many challenges — and for people of color with a rare disease, these challenges are compounded…

Soliris (eculizumab) appears to be safe and effective for patients with hard-to-treat generalized myasthenia gravis (gMG) who have acetylcholine receptor (AChR) antibodies, a study has found. Its benefits were extended to a particular group of patients from the Phase 3 REGAIN clinical trial and its extension study who were treated…

More adults with generalized myasthenia gravis (gMG) who were treated with efgartigimod in a Phase 3 trial experienced minimal or no symptoms than did those given a placebo, an analysis of new study data reported. Other analyses from the ADAPT trial highlighted the potential benefits of efgartigimod for people who are…

The Rare Disease Diversity Coalition (RDDC) awarded $600,000 in grants to ease the disparities faced by rare disease patients of color. These Impact Rare Disease Solution grants will go five RDDC steering committee working groups, which aim to identify problems for rare disease communities and advocate for solutions. The five…

A 60-year-old man with dysphonia — voice issues when trying to speak — was found to have late-onset myasthenia gravis (MG), according to a recent report. Voice changes often come with aging, and this may lead to a delayed or even missed diagnosis of the neuromuscular condition, the researchers…